What are the recommended treatments for menopausal myalgia?

Menopausal Hormone Therapy (MHT) is the most effective treatment for menopausal myalgia

For symptomatic postmenopausal women under age 60 or within 10 years of menopause onset without contraindications, MHT should be offered as first-line therapy for menopausal myalgia, as it addresses the underlying hormonal etiology and improves multiple climacteric symptoms including musculoskeletal pain 1, 2.

Treatment Algorithm

First-Line: Menopausal Hormone Therapy

• Initiate MHT if the patient is:

  • Under 60 years old OR within 10 years of menopause onset
  • No contraindications (history of breast cancer, cardiovascular disease, venous thromboembolism)
  • Experiencing bothersome myalgia alongside other menopausal symptoms 1

• Formulation selection:

  • Women with intact uterus: Combined estrogen-progestogen therapy (EPT) 1
  • Women post-hysterectomy: Estrogen therapy (ET) alone 1
  • Alternative where available: CEE/bazedoxifene combination 1
  • Alternative where available: Tibolone (but NOT in women with breast cancer history) 1

Second-Line: Non-Hormonal Pharmacotherapy

For women who decline MHT or have contraindications, consider:

• SSRIs/SNRIs (selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors) 1
• Gabapentin or pregabalin 1
• Clonidine if not responding to above options 1

Adjunctive Conservative Measures

Regardless of pharmacotherapy choice:

• Weight reduction if BMI elevated (higher BMI significantly worsens both menopausal symptoms and musculoskeletal pain burden) 3
• Physical exercise 4
• Simple analgesia (paracetamol, NSAIDs) for breakthrough pain 3
• Address comorbid factors: sleep disturbance, depression, fatigue 4

Critical Evidence Discussion

The Endocrine Society guideline 1 establishes MHT as the most effective treatment for climacteric symptoms broadly, though it doesn't specifically isolate myalgia. However, recent research confirms that musculoskeletal symptoms including myalgia improve with HRT 2. The 2025 review explicitly states "myalgia may improve with HRT" 2.

Important caveat: While myalgia frequently accompanies menopause and appears hormonally mediated 5, 4, if a patient has concurrent fibromyalgia, this requires separate management. MHT should NOT be prescribed solely for fibromyalgia management 6. However, if climacteric syndrome coexists with fibromyalgia (which occurs in 51-72% of cases) 3, 6, MHT remains appropriate for the menopausal symptoms.

Screening Requirements Before Initiating MHT

• Cardiovascular risk assessment 1
• Breast cancer risk assessment 1
• Screen for contraindications to estrogen therapy

Duration and Monitoring

• Revisit continuation decision annually 1
• Target shortest duration consistent with symptom control 1
• For women with premature/early menopause, continue until age of natural menopause (~51 years) 1

Common Pitfalls to Avoid

• Do not withhold MHT from appropriate candidates based solely on outdated fears from the Women's Health Initiative—benefits exceed risks in women under 60 or within 10 years of menopause 1
• Do not prescribe MHT for fibromyalgia alone without climacteric symptoms 6
• Do not ignore elevated BMI—it independently worsens both menopausal symptoms and musculoskeletal pain 3
• Do not use tibolone in women with breast cancer history 1